Clinical Significance of PD-L1 Expression in Both Cancer and Stroma Cells of Cholangiocarcinoma Patients

Yuki Kitano,Yo-ichi Yamashita,Yosuke Nakao,Rumi Itoyama,Toshihiko Yusa,Naoki Umezaki,Masayo Tsukamoto,Takanobu Yamao,Tatsunori Miyata,Shigeki Nakagawa,Hirohisa Okabe,Katsunori Imai,Akira Chikamoto,Takatoshi Ishiko,Hideo Baba

Clinical Significance of PD-L1 Expression in Both Cancer and Stroma Cells of Cholangiocarcinoma Patients

2019

Yuki Kitano
Yo-ichi Yamashita
Yosuke Nakao
Rumi Itoyama
Toshihiko Yusa
Naoki Umezaki
Masayo Tsukamoto
Takanobu Yamao
Tatsunori Miyata
Shigeki Nakagawa
Hirohisa Okabe
Katsunori Imai
Akira Chikamoto
Takatoshi Ishiko
Hideo Baba

Background The clinical significance of programmed death 1 and its ligand (PD-L1) as therapeutic targets has been reported previously. This study aimed to investigate the clinical impact of PD-L1 expression in cancer and stroma cells in cholangiocarcinoma (CCA).

Keywords:

Stromal cell
Medicine
Clinical significance
PD-L1
Pathology
Cancer
Cancer research
CD163
Immune system
Surgical oncology
Cancer cell
Immunohistochemistry

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations